Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 50.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,531 shares of the company's stock after purchasing an additional 10,588 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.10% of Medpace worth $10,476,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of MEDP. Proficio Capital Partners LLC increased its position in shares of Medpace by 34,497.4% during the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after purchasing an additional 241,827 shares during the period. Raymond James Financial Inc. acquired a new position in Medpace during the fourth quarter worth $78,144,000. Norges Bank bought a new stake in shares of Medpace during the 4th quarter worth $69,859,000. GW&K Investment Management LLC lifted its position in shares of Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock worth $91,516,000 after purchasing an additional 133,379 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in shares of Medpace by 738.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 120,928 shares of the company's stock worth $40,176,000 after acquiring an additional 106,498 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Trading Down 1.0 %

Shares of NASDAQ MEDP traded down $2.82 during mid-day trading on Thursday, hitting $293.68. The company had a trading volume of 288,386 shares, compared to its average volume of 323,423. The stock's 50-day moving average price is $320.31 and its 200-day moving average price is $333.83. Medpace Holdings, Inc. has a 1 year low of $272.00 and a 1 year high of $459.77. The company has a market capitalization of $8.88 billion, a price-to-earnings ratio of 23.30, a P/E/G ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Robert W. Baird boosted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Leerink Partners assumed coverage on Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and reduced their price target for the company from $370.00 to $328.00 in a report on Monday. Finally, Truist Financial decreased their price objective on Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a report on Thursday, April 10th. Ten research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $357.50.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.